NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Price Target & More

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals announced that its Board of Directors has initiated a share repurchase plan on Wednesday, March 28th 2018, which allows the company to buyback $7,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.7% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's board of directors believes its stock is undervalued.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) announced its quarterly earnings results on Wednesday, May, 2nd. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.08. The company had revenue of $33.29 million for the quarter, compared to analysts' expectations of $29.60 million. Avadel Pharmaceuticals had a net margin of 18.96% and a negative return on equity of 13.95%. View Avadel Pharmaceuticals' Earnings History.

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Avadel Pharmaceuticals.

3 brokers have issued twelve-month price targets for Avadel Pharmaceuticals' shares. Their predictions range from $14.00 to $30.00. On average, they expect Avadel Pharmaceuticals' stock price to reach $22.6667 in the next twelve months. View Analyst Ratings for Avadel Pharmaceuticals.

Some companies that are related to Avadel Pharmaceuticals include Epizyme (EPZM), Eagle Pharmaceuticals (EGRX), Intra-Cellular Therapies (ITCI), Reata Pharmaceuticals (RETA), Flexion Therapeutics (FLXN), Endocyte (ECYT), CytomX Therapeutics (CTMX), Dynavax Technologies (DVAX), MacroGenics (MGNX), Vanda Pharmaceuticals (VNDA), Kiniksa Pharmaceuticals Cl A (KNSA), Assembly Biosciences (ASMB), Karyopharm Therapeutics (KPTI), OptiNose (OPTN) and Amarin (AMRN).

Media stories about AVDL stock have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Avadel Pharmaceuticals earned a news impact score of 0.14 on Accern's scale. They also gave media coverage about the company an impact score of 45.71 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Avadel Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.92%), BlackRock Inc. (1.28%), GSA Capital Partners LLP (0.79%), California Public Employees Retirement System (0.23%), Alps Advisors Inc. (0.13%) and Trexquant Investment LP (0.11%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, Francis Fildes, Greg J Divis, Guillaume Cerutti, Healthcare Master Fun Broadfin, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.

AVDL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and BlackRock Inc.. Company insiders that have sold Avadel Pharmaceuticals company stock in the last year include Craig R Stapleton and Healthcare Master Fun Broadfin. View Insider Buying and Selling for Avadel Pharmaceuticals.

AVDL stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Trexquant Investment LP, O Shaughnessy Asset Management LLC, Alps Advisors Inc. and California Public Employees Retirement System. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton, Greg J Divis, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $6.27.

Avadel Pharmaceuticals has a market capitalization of $277.06 million and generates $172.74 million in revenue each year. The company earns $68.27 million in net income (profit) each year or $0.31 on an earnings per share basis. Avadel Pharmaceuticals employs 180 workers across the globe.

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at [email protected]